Literature DB >> 8950049

Nasal administration of morphine-6-glucuronide in sheep--a pharmacokinetic study.

L Illum1, S S Davis, M Pawula, A N Fisher, D A Barrett, N F Farraj, P N Shaw.   

Abstract

The pharmacokinetics of morphine-6-glucuronide (M6G) after both intravenous dosing and nasal administration were studied in sheep. The nasal formulation consisted of M6G in combination with an absorption promoting delivery system in the form of chitosan. The mean half-life of M6G after intravenous administration was 51.0 +/- 8.2 min and that after intranasal dosing was 45.0 +/- 5.5 min. M6G clearance and volume of distribution were 5.4 +/- 1.5 mL min-1 kg-1 and 0.4 +/- 0.1 L kg-1 respectively. The plasma profile after nasal administration demonstrated rapid absorption of M6G. The bioavailability of M6G in the chitosan formulation was found to be 31.4%. These results suggest that M6G administered in combination with the chitosan delivery system may be considered as a suitable non-parenteral means of administering this analgesic.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8950049     DOI: 10.1002/(SICI)1099-081X(199611)17:8<717::AID-BDD985>3.0.CO;2-I

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  7 in total

1.  The effect of blood sampling site and physicochemical characteristics of drugs on bioavailability after nasal administration in the sheep model.

Authors:  L Illum; M Hinchcliffe; S S Davis
Journal:  Pharm Res       Date:  2003-09       Impact factor: 4.200

2.  Intranasal delivery--modification of drug metabolism and brain disposition.

Authors:  Yin Cheong Wong; Zhong Zuo
Journal:  Pharm Res       Date:  2010-04-06       Impact factor: 4.200

3.  Blood-brain distribution of morphine-6-glucuronide in sheep.

Authors:  H H Villesen; D J R Foster; R N Upton; L L Christrup; A A Somogyi; A Martinez; C Grant
Journal:  Br J Pharmacol       Date:  2006-10-03       Impact factor: 8.739

Review 4.  Fentanyl Formulations in the Management of Pain: An Update.

Authors:  Stephan A Schug; Sonya Ting
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

5.  Biovector nanoparticles improve antinociceptive efficacy of nasal morphine.

Authors:  D Betbeder; S Spérandio; J P Latapie; J de Nadai; A Etienne; J M Zajac; B Francés
Journal:  Pharm Res       Date:  2000-06       Impact factor: 4.200

Review 6.  Pharmacokinetics of non-intravenous formulations of fentanyl.

Authors:  Jörn Lötsch; Carmen Walter; Michael J Parnham; Bruno G Oertel; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2013-01       Impact factor: 6.447

7.  In vivo nose-to-brain delivery of the hydrophilic antiviral ribavirin by microparticle agglomerates.

Authors:  Alessandro Giuliani; Anna Giulia Balducci; Elisa Zironi; Gaia Colombo; Fabrizio Bortolotti; Luca Lorenzini; Viola Galligioni; Giampiero Pagliuca; Alessandra Scagliarini; Laura Calzà; Fabio Sonvico
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.